Collaboration - September 17, 2013
AstraZeneca pays $50 million for rights to Merck cancer drug
Merck & Co has licensed its experimental cancer drug to AstraZeneca for a $50 million upfront fee. Under the terms of agreement Merck will also be eligible to receive future payments related to development and regulatory milestones as well as tiered royalties. The drug called MK-1775 is currently in mid-stage trials in combination with standard-of-care […]
MedTech article - July 5, 2013
The fight against cancer
Here’s a sample of some of the latest Nordic medtech and pharma progress in cancer treatments. Cancer is perhaps the hottest area within pharmaceutical research in the world right now. According to the U.S. pharmaceutical industry association PhRMA, there are nearly 1,000 new substances being developed in commercial clinical cancer research run by pharmaceutical companies. […]